Genevac Research Articles

Influence of Gene Vac B vaccine on the abdominal muscle MDA in the immunostimulated male swiss albino mice.

Influence of Gene Vac B vaccine on the abdominal muscle MDA in the immunostimulated male swiss albino mice.

English

Total protein, DNA and RNA was estimated in the abdominal muscles of experimental and control male swiss albino mice (6-8 wks old; 23-26 g wt). Immunex DS (IDS) was orally administered (@150mg/mouse) as a single dose in mice of group I. In a set of 6 experimental groups, IDS was orally administered @150mg/mouse in a single dose on day 0 and injected with Gene Vac B vaccine on day 4 of experiment (@ 0.07ml/mouse, A; 0.1ml/mouse, B; 0.2ml/mouse, C; 0.4ml/mouse, D; 0.8ml/mouse, E, and 1ml/mouse, F). A single group was kept as control (untreated and uninfected). Two mice from all the eight groups were sacrificed on day 8, 9, 10, 11 and 12 after vaccine treatment. Muscle tissue (abdominal) was separated and analysed for total protein, DNA and RNA using standard methods. The level of protein, DNA and RNA showed much alteration in all the experimental groups of mice throughout the infection period when compared with controls and IDS treated mice; this abnormality might be due to IDS and/or pathogenic stress caused by reaction oxygen species.

THE INFLUENCE OF IMMUNEX DS AGAINST EXPERIMENTAL HEPATITIS B VACCINE ON LIVER PROTEIN AND DNA PROFILE OF MICE

A novel drugs known as immunostimulants were developed used in adaptogenic therapies with vaccines to gain much yields in the fields of Aquaculture, Animal husbandry Poultry and live stock management. Such a novel immunostimulant is Immunex DS with a combination of vitamins, minerals, trace elements Beta glucans and probiotics. Swiss albino mice was taken as the experimental model and targeted with the Gene Vac B vaccine to induce experimental Hepatitis B condition. Three categories of mice were maintained viz a Immunex DS treated (Immunostimulated group c) , Immunex DS treated and inoculated with varied doses of Gene Vac B vaccine(groups A,B,C,D,E,and F) and controls (un treated with Immunex DS and un inoculated with Gene Vac B Vaccine) for comparison. The tissues from liver were taken and processed for the content of protein and DNA on the designated days of necropsy. And the findings throws the light on the various dimensions of the Immunex DS in disturbing/impairing the synthesis of proteins and DNA during Gene Vac B induction of pathogenic stress causing experimental hepatitis.

CARBOHYDRATE AND GLYCOGEN CONTENT IN THE ABDOMINAL MUSCLES OF MICE TREATED WITH IMMUNEX DS AND HEPATITIS B VACCINE

The investigations were conducted in 8 groups of male Swiss Albino mice (6-8 wks old; 23-26 g wt). In mice of group I (10), Immunex DS (IDS) was orally administered (@150mg/mouse) as a single dose. In mice (10) of group A, B, C, D, E and F, IDS was given orally @150mg/mouse (single dose) (on day 0) and Gene Vac B vaccine was infected on day 4 of experiment @ 0.07ml/mouse, 0.1ml/mouse, 0.2ml/mouse 0.4ml/mouse, 0.8ml/mouse and 1ml/mouse. Another group (U) of mice (10) was kept untreated (with IDS and uninfected) as controls for comparison. Two mice from each experimental (A, B, C, D, E, and F) and control groups (U) were necropsied after day 7 of vaccine treatment. Abdominal muscle tissue was separated and analysed for total carbohydrate and total glycogen using standard methods. The level of total carbohydrate increased and glycogen decreased markedly from day 1 to 5 of experiment in group A. Mice of group B showed a decrease in the content of carbohydrate and glycogen on day 1 to 2 and a gradual increase from day 2 to 5 of experiment. In mice of group C, the level of carbohydrate decreased on day 1 and 3 and glycogen on day 1 and 2 with an increased content of carbohydrate and glycogen on day 2, 4, 5 and 3, 4 and 5. The content of carbohydrate and glycogen decreased on day 1, 2, 3 and increased on day 4, 5 in mice of group D. Mice of group E decreased level of carbohydrate on day 1, 3 and 4 and glycogen on day 1, 2 and 3 and an increased level of carbohydrate and glycogen on day 2 and 5 and 4 and 5. Mice of group F showed a gradual decrease in the level of carbohydrate from day 1 to 5 and and glycogen on day 1, 2 increased level of glycogen from day 3, 4 and 5 when compared with the control and immunostimulated mice group U and I. The altered level of carbohydrate and glycogen in all the experimental groups might be due to their disturbance in their metabolism.

ALKALINE PHOSPHATASE AND ACID PHOSPHATASE LEVELS IN THE ABDOMINAL MUSCLES OF IMMUNOSTIMULATED MICE DURING HEPATITIS B

The investigations were conducted in 8 groups of male Swiss Albino mice (6-8 wks old; 23-26 g wt). In mice of group I (10), Immunex DS (IDS) was orally administered (@150mg/mouse) as a single dose. In mice (10) of group A, B, C, D, E and F, IDS was given orally @150mg/mouse (single dose) (on day 0) and Gene Vac B vaccine was infected on day 4 of experiment @ 0.07ml/mouse, 0.1ml/mouse, 0.2ml/mouse 0.4ml/mouse, 0.8ml/mouse and 1ml/mouse. Another group (U) of mice (10) was kept untreated (with IDS and uninfected) as controls for comparison. Two mice from each experimental (A, B, C, D, E, and F) and control groups (U) were necropsied after day 7 of vaccine treatment. Abdominal muscle tissue was separated and analysed for total carbohydrate and total glycogen using standard methods. The level of total carbohydrate increased and glycogen decreased markedly from day 1 to 5 of experiment in group A. Mice of group B showed a decrease in the content of carbohydrate and glycogen on day 1 to 2 and a gradual increase from day 2 to 5 of experiment. In mice of group C, the level of carbohydrate decreased on day 1 and 3 and glycogen on day 1 and 2 with an increased content of carbohydrate and glycogen on day 2, 4, 5 and 3, 4 and 5. The content of carbohydrate and glycogen decreased on day 1, 2, 3 and increased on day 4, 5 in mice of group D. Mice of group E decreased level of carbohydrate on day 1, 3 and 4 and glycogen on day 1, 2 and 3 and an increased level of carbohydrate and glycogen on day 2 and 5 and 4 and 5. Mice of group F showed a gradual decrease in the level of carbohydrate from day 1 to 5 and and glycogen on day 1, 2 increased level of glycogen from day 3, 4 and 5 when compared with the control and immunostimulated mice group U and I. The altered level of carbohydrate and glycogen in all the experimental groups might be due to their disturbance in their metabolism.

English

Hepatitis B infection and its sequel continue to be a worldwide health problem, especially in the developing countries. The pool of chronic carriers of hepatitis B virus is built up in childhood and is then maintained in older children and adults. Therefore, it is important to give protection during infancy. Effective vaccines to prevent hepatitis B infection are available. This study was undertaken to evaluate the immune response and reactogenicity of two recombinant hepatitis B vaccines available in Indian market, in normal healthy infants. Infants of 6-8 weeks of age were screened for eligibility criteria. All the eligible subjects had negative baseline serum HBsAg and anti-HBs. The subjects received three doses of 10 µg of Gene Vac-B or Engerix-B at 6, 10 and 14 weeks of age. GeneVac-B is an indigenously manufactured vaccine, while Engerix-B is an imported vaccine. The vaccinees were assessed for immune response and safety parameters. The anti-HBs antibody titer was obtained 1 month after 3rd dose of vaccine and was considered seroconverted if more than 1 mIU/ml, and seroprotective if more than 10 mIU/ml. Total of 126 subjects were considered for analysis. One month after 3rd dose, seroconversion was 100% for both the vaccines and seroprotection was 94.36% for Gene Vac-B, and 92.72% for Engerix B. The GMT of anti- HBs antibodies were 149.47 mIU/ml for Gene Vac- B and 153.28 mIU/ml for Engerix B. Four cases of incessant cry were observed during the study period. The indigenous vaccine, Gene Vac-B and the imported vaccine, Engerix-B showed high immunogenicity and safety profile in Indian infant population. Both vaccines were comparable.   Key words: Hepatitis-B vaccine, gene vac-B, infants, immunogenicity, reactogenicity.